Oligonucleotide CDMO Market Expands as Demand for Nucleic Acid-Based Therapeutics Grows | Valuates Reports

Oligonucleotide CDMO Market Size
The global market for Oligonucleotide CDMO was valued at US$ 1250 million in the year 2024 and is projected to reach a revised size of US$ 2839 million by 2031, growing at a CAGR of 12.5% during the forecast period.

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-10N18969/Global_Oligonucleotide_CDMO_Market_Research_Report_2025

Oligonucleotide CDMO Market Trends

The Oligonucleotide CDMO market size is experiencing strong growth due to increasing demand for custom nucleic acid synthesis in pharmaceuticals, biotechnology, and diagnostics. With advancements in gene therapy, RNA-based therapeutics, and personalized medicine, Contract Development and Manufacturing Organizations (CDMOs) are playing a crucial role in providing high-quality, scalable, and regulatory-compliant oligonucleotide manufacturing services. This trend is driving market growth as pharmaceutical companies focus on outsourcing production to specialized providers.

In terms of market share, North America and Europe lead the industry due to strong biopharmaceutical R&D investments and established regulatory frameworks. However, the Asia-Pacific region is emerging as a high-growth market, with increasing biotech collaborations, government support for precision medicine, and expanding manufacturing capabilities. Key industry players are focusing on process optimization, cost efficiency, and GMP-certified large-scale production to meet rising market demands.

A comprehensive market analysis highlights the increasing reliance on CDMOs for streamlined oligonucleotide synthesis, purification, and formulation development. With RNA-based drug approvals, mRNA vaccines, and antisense therapies gaining traction, the Oligonucleotide CDMO market revenue is expected to grow significantly, supported by technological advancements, strategic partnerships, and the expanding role of nucleic acid-based treatments in modern medicine.

Segment by Type

• APIs and Intermediates
• FDF

Segment by Application

• Pharmaceutical and Biotechnology Companies
• Research Institutes
• Others

By Company

Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, Sylentis, Ajinomoto Bio-Pharma, EUROAPI, Veliter, PolyPeptide Group, CordenPharma, Thermofischer, Bio Basic, Genscript, Cytiva, ScinoPharm, CBL, Piramal Pharma, CPC Scientific, Eurogentec, Cambrex, WuXi STA

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-10N18969/global-oligonucleotide-cdmo

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.